FDA
-
-
-
-
-
-
-
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
-
-
-
-
-
-
-
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement
-
-
-
-
-
-
-
Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
-
-
-
-
-
-
-
Santhera will Publish its 2021 Annual Report by June 3, 2022, and Hold its Annual General Meeting on June 29, 2022
-
-
-
-
-
-
-
Santhera Completes Repayment of 2017/22 Convertible Bonds
-
322,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

